Skip to main content
Erschienen in:

14.03.2022 | Original Article

The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions

verfasst von: Xia Bi, Zachary French, Neil Palmisiano, Kuang-Yi Wen, Lindsay Wilde

Erschienen in: Annals of Hematology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Cigarette smoking has been associated with increased risk of developing acute myeloid leukemia (AML) in adults. There is limited data on the impact of smoking in AML patients with certain cytogenetic abnormalities. The aim of this study is to assess whether cigarette smoking affected the survival outcome of patients with newly diagnosed AML with TP53 alterations. We conducted a retrospective study of patients who were diagnosed with AML at the Thomas Jefferson Hospital with presence of TP53 mutations and/or 17p deletions. Patients’ sex, age, race, smoking status (ever vs. never), cytogenetics, mutational profile, induction regimen, and induction response were analyzed. A total of 102 patients were included in the study with a median follow-up of 27.8 months. Among 100 patients who had documentation of smoking status, 59 patients (59%) were ever-smokers and 41 (41%) were never-smokers. Kaplan–Meier survival analysis showed that never-smokers did not differ in overall survival (OS) when compared to ever-smokers (P = 0.34). Univariate analysis revealed that age and cytogenetics had a statistically significant impact on survival. In multivariate analysis incorporating sex, age, race, smoking status, cytogenetics, and induction regimen as covariates, cytogenetics and induction regimen were independent prognostic factors for OS. In summary, no significant difference in OS was found between ever- and never-smokers in AML patients with TP53 alterations. Additional studies are needed to examine the prognostic impact of cigarette smoking in AML with specific cytogenetic abnormalities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136–1152CrossRef Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136–1152CrossRef
2.
Zurück zum Zitat Cancer Genome Atlas Research, N., et al., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 2013. 368(22): p. 2059–74. Cancer Genome Atlas Research, N., et al., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 2013. 368(22): p. 2059–74.
3.
Zurück zum Zitat Papaemmanuil E et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221CrossRef Papaemmanuil E et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221CrossRef
4.
Zurück zum Zitat Kaiser AM, Attardi LD (2018) Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ 25(1):93–103CrossRef Kaiser AM, Attardi LD (2018) Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ 25(1):93–103CrossRef
5.
Zurück zum Zitat Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310CrossRef Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310CrossRef
6.
Zurück zum Zitat Wang XW, Harris CC (1996) TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surv 28:169–196PubMed Wang XW, Harris CC (1996) TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surv 28:169–196PubMed
7.
Zurück zum Zitat Petitjean A et al (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165CrossRef Petitjean A et al (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165CrossRef
8.
Zurück zum Zitat Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113(2):433–439CrossRef Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113(2):433–439CrossRef
9.
Zurück zum Zitat Petitjean A et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629CrossRef Petitjean A et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629CrossRef
10.
Zurück zum Zitat Malkin D et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238CrossRef Malkin D et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238CrossRef
11.
Zurück zum Zitat Olivier, M., M. Hollstein, and P. Hainaut, TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol, 2010. 2(1): p. a001008. Olivier, M., M. Hollstein, and P. Hainaut, TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol, 2010. 2(1): p. a001008.
12.
Zurück zum Zitat Prokocimer M, Molchadsky A, Rotter V (2017) Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood 130(6):699–712CrossRef Prokocimer M, Molchadsky A, Rotter V (2017) Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood 130(6):699–712CrossRef
14.
Zurück zum Zitat Pfeifer GP et al (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21(48):7435–7451CrossRef Pfeifer GP et al (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21(48):7435–7451CrossRef
15.
Zurück zum Zitat Thomas X, Chelghoum Y (2004) Cigarette smoking and acute leukemia. Leuk Lymphoma 45(6):1103–1109CrossRef Thomas X, Chelghoum Y (2004) Cigarette smoking and acute leukemia. Leuk Lymphoma 45(6):1103–1109CrossRef
16.
Zurück zum Zitat Brownson RC, Novotny TE, Perry MC (1993) Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med 153(4):469–475CrossRef Brownson RC, Novotny TE, Perry MC (1993) Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med 153(4):469–475CrossRef
17.
Zurück zum Zitat Snyder R (2012) Leukemia and benzene. Int J Environ Res Public Health 9(8):2875–2893CrossRef Snyder R (2012) Leukemia and benzene. Int J Environ Res Public Health 9(8):2875–2893CrossRef
18.
Zurück zum Zitat Zhu J. et al. (2013) Comparison of toxicity of benzene metabolite hydroquinone in hematopoietic stem cells derived from murine embryonic yolk sac and adult bone marrow. PLoS One 8(8):e71153 Zhu J. et al. (2013) Comparison of toxicity of benzene metabolite hydroquinone in hematopoietic stem cells derived from murine embryonic yolk sac and adult bone marrow. PLoS One 8(8):e71153
19.
Zurück zum Zitat Bjork J et al (2000) Smoking and myelodysplastic syndromes. Epidemiology 11(3):285–291CrossRef Bjork J et al (2000) Smoking and myelodysplastic syndromes. Epidemiology 11(3):285–291CrossRef
20.
Zurück zum Zitat Sandler DP et al (1993) Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst 85(24):1994–2003CrossRef Sandler DP et al (1993) Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst 85(24):1994–2003CrossRef
21.
Zurück zum Zitat Moorman AV et al (2002) Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. Br J Cancer 86(1):60–62CrossRef Moorman AV et al (2002) Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. Br J Cancer 86(1):60–62CrossRef
22.
Zurück zum Zitat Davico L et al (1998) Chromosome 8, occupational exposures, smoking, and acute nonlymphocytic leukemias: a population-based study. Cancer Epidemiol Biomarkers Prev 7(12):1123–1125PubMed Davico L et al (1998) Chromosome 8, occupational exposures, smoking, and acute nonlymphocytic leukemias: a population-based study. Cancer Epidemiol Biomarkers Prev 7(12):1123–1125PubMed
23.
Zurück zum Zitat Alfayez M, et al. (2019) Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. J Clin Oncol 37(15_suppl):7002–7002 Alfayez M, et al. (2019) Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. J Clin Oncol 37(15_suppl):7002–7002
24.
Zurück zum Zitat Sasaki K et al (2020) Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765–774CrossRef Sasaki K et al (2020) Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765–774CrossRef
25.
Zurück zum Zitat Deng J et al (2020) The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis. Eur J Haematol 105(5):524–539CrossRef Deng J et al (2020) The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis. Eur J Haematol 105(5):524–539CrossRef
26.
Zurück zum Zitat Dohner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRef Dohner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRef
27.
Zurück zum Zitat Stengel A et al (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31(3):705–711CrossRef Stengel A et al (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31(3):705–711CrossRef
28.
Zurück zum Zitat Welch JS et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023–2036CrossRef Welch JS et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023–2036CrossRef
29.
Zurück zum Zitat Seifert H et al (2009) The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 23(4):656–663CrossRef Seifert H et al (2009) The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 23(4):656–663CrossRef
30.
Zurück zum Zitat Mareschal S et al (2021) Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Adv 5(4):1003–1016CrossRef Mareschal S et al (2021) Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Adv 5(4):1003–1016CrossRef
31.
Zurück zum Zitat Grimwade D, Ivey A, Huntly BJ (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127(1):29–41CrossRef Grimwade D, Ivey A, Huntly BJ (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127(1):29–41CrossRef
32.
Zurück zum Zitat Fircanis S et al (2014) The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol 89(8):E125–E132CrossRef Fircanis S et al (2014) The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol 89(8):E125–E132CrossRef
33.
Zurück zum Zitat Bjork J et al (2001) Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. Leuk Res 25(10):865–872CrossRef Bjork J et al (2001) Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. Leuk Res 25(10):865–872CrossRef
34.
Zurück zum Zitat Varadarajan R et al (2012) Smoking adversely affects survival in acute myeloid leukemia patients. Int J Cancer 130(6):1451–1458CrossRef Varadarajan R et al (2012) Smoking adversely affects survival in acute myeloid leukemia patients. Int J Cancer 130(6):1451–1458CrossRef
35.
Zurück zum Zitat Kristensen D et al (2020) The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - a Danish nationwide cohort study. Br J Haematol 190(2):236–243CrossRef Kristensen D et al (2020) The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - a Danish nationwide cohort study. Br J Haematol 190(2):236–243CrossRef
36.
Zurück zum Zitat Goldvaser H et al (2017) The association between smoking and breast cancer characteristics and outcome. BMC Cancer 17(1):624CrossRef Goldvaser H et al (2017) The association between smoking and breast cancer characteristics and outcome. BMC Cancer 17(1):624CrossRef
37.
Zurück zum Zitat Chen SY, et al. (2021) 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Am J Otolaryngol 42(3):102915 Chen SY, et al. (2021) 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Am J Otolaryngol 42(3):102915
Metadaten
Titel
The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions
verfasst von
Xia Bi
Zachary French
Neil Palmisiano
Kuang-Yi Wen
Lindsay Wilde
Publikationsdatum
14.03.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 6/2022
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04812-z

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

HCL-Systeme bei Typ-1-Diabetes: Blutzuckerkontrolle besser, Risiko für Ketoazidose aber höher

Eine bessere Blutzuckerkontrolle und weniger Fälle von hypoglykämischem Koma, dafür mehr diabetische Ketoazidosen. Dieses HCL-Insulin-Therapie-Profil zeigte sich in einem Vergleich von Hybrid-Closed-Loop(HCL)- und Open-Loop-Systemen bei Typ-I-Diabetes im DPV-Register.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Möglicher Zusatzeffekt von SGLT-2-Hemmern und GLP-1-Analoga bei COPD

Menschen mit Typ-2-Diabetes, die gleichzeitig an COPD leiden, könnten von der Behandlung mit SGLT-2-Hemmern und GLP-1-Rezeptoragonisten doppelt profitieren: Eine Analyse aus den USA deutet auf ein vermindertes Exazerbationsrisiko hin.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.